This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

Moderna (NASDAQ:MRNA) was among the notable gainers on Wednesday after Oracle (NYSE:ORCL) Chairman Larry Ellison highlighted the AI's potential in the development of messenger RNA-based cancer ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018 ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an ...

After layoffs in 2024, Takeda is gearing up for a big 2025 that includes preparations to launch three new medicines, hiring, ...

The company offers clinical trials that are up to three times faster and produce demonstrably better quality trial data than traditional players. The Series B was led by Balderton Capital and will be ...